- Acne
- Actinic Keratosis
- Aesthetics
- Alopecia
- Atopic Dermatitis
- Buy-and-Bill
- COVID-19
- Case-Based Roundtable
- Chronic Hand Eczema
- Drug Watch
- Eczema
- General Dermatology
- Hidradenitis Suppurativa
- Melasma
- NP and PA
- Pediatric Dermatology
- Pigmentary Disorders
- Practice Management
- Precision Medicine and Biologics
- Prurigo Nodularis
- Psoriasis
- Psoriatic Arthritis
- Rare Disease
- Rosacea
- Skin Cancer
- Vitiligo
- Wound Care
Opinion
Video
Systemic Treatment Options for Atopic Dermatitis
Author(s):
The panelist discusses how systemic atopic dermatitis (AD) treatment involves biologics and Janus kinase inhibitors for moderate to severe cases, targeting inflammation and itch with individualized approach based on patient factors, offering significant symptom improvement and skin barrier restoration.
Video Player is loading.
Video content above is provided by the following:
- Describe your approach to initiating systemic treatment in patients with AD. At what point do you consider systemic treatment for your patients?
- Does your approach differ based on patient age or other factors?
- Briefly discuss the systemic agents that are currently FDA-approved for AD, including how they work to address itch and skin lesions, as well as efficacy and safety data.
- Dupilumab, lebrikizumab, tralokinumab, nemolizumab
- Abrocitinib, upadacitinib
Related Videos
Recapping the Evolving Treatment Landscape for Atopic Dermatitis
Sunscreen Ingredients for UV and Visible Light Protection
The Solar Spectrum and Impact on Skin Health
Discussing Efficacy and Safety of JAK Inhibitors With Patients and Caregivers
Patient Considerations for Selecting Treatment for a 16-Year-Old Male With Severe Alopecia Areata
Future Directions for Pediatric Atopic Dermatitis Management and Research
New Systemic Therapies for Pediatric Atopic Dermatitis: Nemolizumab and Oral JAK Inhibitors
The JAK-STAT Signaling Pathway and Its Role in Atopic Dermatitis
Selecting Systemic Therapy for Patients with Moderate to Severe Atopic Dermatitis
Pipeline Updates on the Horizon From Arcutis Biotherapeutics
Related Content
